Cardiovascular Outcome of Cancer Patients: The "GMEDICO Cohort"
Assistance Publique Hopitaux De Marseille
530 participants
Jul 5, 2019
INTERVENTIONAL
Conditions
Summary
The Mediterranean Group of Cardio-Oncology (GMEDICO) brings together French cardiologists and oncologists who have developed a protocol for the monitoring and cardio-oncological management of patients treated for cancer. This unique organization makes it possible to envisage the creation of a large cohort from which the incidence and predictive factors of cardiovascular toxicity can be determined. Primary objective: to determine the cardiovascular prognosis of patients treated for cancer and followed up in cardio-oncology. Secondary objectives * To determine the clinical, biological and imaging factors associated with cardiovascular events under cancer treatment, in order to define a risk score including clinical, biological (biomarker) and imaging data. * To create a biological source for testing other biomarkers and conducting genome-wide association studies and genetic factors associated with cardiovascular events under cancer treatment.
Eligibility
Inclusion Criteria1
- All adults referred for specialist cardio-oncology consultations before the initiation of a cancer treatment according to pre-established indications will be eligible.
Exclusion Criteria3
- Failure to provide information that makes it impossible to complete a consultation form or refuse to sign the consent.
- Minor or major patient under guardianship
- Pregnant or breastfeeding woman
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
blood samples
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03492528